Immuneering Corp Ordinary Shares Class A IMRX 深 沪
已收盘 09-26 16:00:00 美东时间
8.08
+0.080
+1.00%
华盛通- 最 高8.29
- 今 开8.18
- 成交量 600.87万股
- 最 低 7.5201
- 昨 收 8.00
- 总市值 3.36亿
- 52周最高 10.08
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 1.10
- 委 比 93.42%
- 总股本 4157.02万
- 历史最高 33.99
- 量 比 0.91
- 振 幅 9.62%
- 历史最低 1.00
- 每 手 1
- 风险率 2.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
09-26 09:45
Immuneering Announces Public Offering to Raise $164.1M
The latest update is out from Immuneering ( ($IMRX) ). On September 24, 2025, I...
09-26 05:47
Biggest stock movers Thursday: INTC, RIG, and more
Stock futures ticked higher in the premarket hours of Thursday as investors awaited the release of key jobs data, hoping for signals on labor market strength and its potential impact on future Federal...
09-25 17:00
Immuneering Announces $25M Securities Purchase Agreement
Immuneering ( ($IMRX) ) has provided an update. On September 24, 2025, Immuneer...
09-25 16:49
Immuneering shares are trading higher after the company reported 86% overall survival at 9 months in first-line pancreatic cancer patients treated with Atebimetinib plus mGnP.
Immuneering shares are trading higher after the company reported 86% overall su...
09-25 04:03
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
Immuneering Corporation announced a proposed underwritten public offering of its Class A common stock or pre-funded warrants, alongside a private placement with Sanofi for $25 million. Proceeds will fund the advancement of preclinical and clinical development of product candidates and general corporate purposes. Leerink Partners and Oppenheimer & Co. Inc. are acting as joint bookrunners and placement agents. The offering is subject to market cond...
09-24 20:05
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
Immuneering Corporation reported updated data from their Phase 2a trial of atebimetinib in combination with mGnP for first-line pancreatic cancer. The study showed impressive results with 86% overall survival (OS) and 53% progression-free survival (PFS) at 9 months, significantly outperforming standard care benchmarks. Atebimetinib's favorable tolerability profile and innovative mechanism as a Deep Cyclic Inhibitor targeting MEK suggest potential...
09-24 20:01
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
<p>Immuneering Corporation announced the appointment of Thomas J. Schall, Ph.D., as Chairman of its Board of Directors. Dr. Schall, a seasoned biotech executive and scientist with over 30 years of experience, is known for founding ChemoCentryx and leading the development of Tavneos, which was approved by the FDA and led to the company's acquisition by Amgen for nearly $4 billion. His expertise is expected to strengthen Immuneering's progress in a...
09-16 11:00
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
Biotech Firm Immuneering Plans Key Cancer Data Presentations At Upcoming Boston Summits
Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today shared plans to announce updated overall survival data in first-line pancreatic cancer patients
09-10 19:12
